---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-014236"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2024-04-02T23:59:59+00:00"
generated_at: "2026-06-04T03:25:09.412671+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ocugen provides FY2023 update: FDA alignment for OCU400 Phase 3, RMAT designation, cash $39.5M, restatement planned

## Summary
- FDA alignment for broad retinitis pigmentosa indication in Phase 3 trial of OCU400; RMAT designation granted.
- Completed cohort 1 dosing for OCU410 (GA) and OCU410ST (Stargardt) in Phase 1/2 trials.
- Cash, cash equivalents, and investments $39.5M as of Dec 31, 2023, vs. $90.9M a year earlier; runway into Q4 2024.
- Intends to restate FY2022 and first three quarters of 2023 financials due to non-cash accounting error; no cash impact.
- OCU500 mucosal vaccine selected for NIAID Project NextGen; clinical trials expected mid-2024.

## SEC filing metadata
- accession: 0001628280-24-014236
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2024-04-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000162828024014236/0001628280-24-014236-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000162828024014236/ocgn-20240402.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-014236
- JSON: https://secwatch.observer/filing/0001628280-24-014236.json
- Plain text: https://secwatch.observer/filing/0001628280-24-014236.txt

## Key facts
- Earnings Releases
  Ocugen, Inc. reported financial results for the fourth quarter and the fiscal year ended December 31, 2023.
  - Period: the fourth quarter and the fiscal year ended December 31, 2023
  - Result: reported results
  source text: On April 2, 2024, Ocugen, Inc. (the "Company") issued a press release announcing certain financial data for the fourth quarter and the fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372299/000162828024014236/0001628280-24-014236-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.